Healthcare utilization and associated outcomes among people who inject drugs

Lianping Ti
Research Associate (Urban Health Research Initiative, BC-CfE)


This talk is open to the public
A light lunch will be served

The Forefront Lectures are accredited for 1.0 Mainpro-M1 credit (College of Family Physicians of Canada)

Lianping Ti is a Research Associate with the Urban Health Research Initiative of the BC Centre for Excellence in HIV/AIDS and is completing her PhD in the School of Population and Public Health at the University of British Columbia. Originally from Thailand, she has research interests in illicit drug use, infectious diseases, and health services research, and works on projects in Vancouver and Bangkok. She currently holds several awards, including a CIHR Doctoral Research Award, which supports her PhD research.


Event Details

Days
Hours
Minutes
Seconds
Start Date
End Date
Event Category
Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below